GPR40 agonist 4 is primarily used in research focused on diabetes management. It activates the GPR40 receptor, which is involved in enhancing glucose-stimulated insulin secretion from pancreatic beta cells. This mechanism makes it a potential candidate for developing treatments for type 2 diabetes. Researchers study its effects to understand how it can improve glycemic control and reduce blood sugar levels. Additionally, it is explored for its role in modulating fatty acid metabolism, which could provide further therapeutic benefits in metabolic disorders. Its application is mainly confined to preclinical studies, aiming to evaluate its efficacy and safety for future drug development.